
HeartFlow Inc (HTFL) Stock Forecast & Price Target
HeartFlow Inc (HTFL) Analyst Ratings
Bulls say
HeartFlow Inc. demonstrated significant performance in 3Q25, with revenues reaching $46.3 million, marking a year-over-year growth of approximately 41% and surpassing consensus projections driven by strong adoption of its FFR-CT coronary disease analysis software. The company’s gross margins improved to 76.8%, reflecting a solid operational efficiency and profitability trajectory as it continues to expand its user base and account penetration in the market. Looking forward, HeartFlow’s core business fundamentals remain robust, supported by ongoing growth in coronary CT angiography and the anticipated contribution of plaque analysis revenues, positioning the company for sustainable revenue growth in the mid-20s percentage range over the coming years.
Bears say
HeartFlow Inc. has reported substantial net losses of $95.7 million in FY23 and $96.4 million in FY24, with expectations of incurring further significant losses in the future, raising concerns about the company's ability to achieve profitability. Furthermore, the growth prospects are hindered by potential reimbursement risks, as inadequate coverage from third-party payors could negatively affect the adoption of its HeartFlow Platform among healthcare providers. The projected revenue guidance for 2025 of $173 million suggests only flat growth moving into 4Q25, indicating a lack of momentum in revenue generation amidst existing operational challenges.
This aggregate rating is based on analysts' research of HeartFlow Inc and is not a guaranteed prediction by Public.com or investment advice.
HeartFlow Inc (HTFL) Analyst Forecast & Price Prediction
Start investing in HeartFlow Inc (HTFL)
Order type
Buy in
Order amount
Est. shares
0 shares